Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

Lisa M. Dunkle, Karen L. Kotloff, Cynthia L. Gay, View ORCID ProfileGermán Áñez, Jeffrey M. Adelglass, Alejandro Q. Barrat Hernández, Wayne L. Harper, Daniel M. Duncanson, Monica A. McArthur, Diana F. Florescu, R. Scott McClelland, Veronica Garcia-Fragoso, Robert A. Riesenberg, David B. Musante, David L. Fried, Beth E. Safirstein, Mark McKenzie, Robert J. Jeanfreau, Jeffrey K. Kingsley, Jeffrey A. Henderson, Dakotah C. Lane, Guillermo M. Ruíz-Palacios, Lawrence Corey, Kathleen M. Neuzil, Robert W. Coombs, Alex L. Greninger, Julia Hutter, Julie A. Ake, Katherine Smith, Wayne Woo, Iksung Cho, Gregory M. Glenn, Filip Dubovsky, for the 2019nCoV-301 Study Group
doi: https://doi.org/10.1101/2021.10.05.21264567
Lisa M. Dunkle
1Novavax, Gaithersburg, Maryland
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: LDunkle{at}novavax.com
Karen L. Kotloff
2University of Maryland School of Medicine, Baltimore, Maryland
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia L. Gay
11University of North Carolina School of Medicine, Chapel Hill, North Carolina
M.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Germán Áñez
1Novavax, Gaithersburg, Maryland
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Germán Áñez
Jeffrey M. Adelglass
7Research Your Health, Plano, Texas
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandro Q. Barrat Hernández
5FAICIC Clinical Research, Veracruz, Mexico
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wayne L. Harper
9M3-Wake Research, Raleigh, North Carolina
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel M. Duncanson
12SIMEDHealth, Gainesville, Florida
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica A. McArthur
2University of Maryland School of Medicine, Baltimore, Maryland
M.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana F. Florescu
14University of Nebraska Medical Center, Omaha, NE, Washington
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Scott McClelland
15University of Washington Medical Center, Washington
M.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Veronica Garcia-Fragoso
8Texas Center for Drug Development, Houston, Texas
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. Riesenberg
18Atlanta Center for Medical Research, Atlanta, Georgia
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David B. Musante
10M3-Emerging Medical Research, Durham, North Carolina
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David L. Fried
20Velocity Clinical Research - Providence, Warwick, RI
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beth E. Safirstein
13Velocity Clinical Research - Hallandale Beach, Hallandale Beach, Florida
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark McKenzie
21WR ClinSearch, Chattanooga, TN
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Jeanfreau
22MedPharmics, Metairie, LA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey K. Kingsley
19IACT Health, Columbus, Georgia
D.O., M.B.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey A. Henderson
23Black Hills Center for American Indian Health, Rapid City, SD
M.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dakotah C. Lane
17Lummi Indian Health Center, Bellingham, Washington
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillermo M. Ruíz-Palacios
6Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Mexico City, Mexico
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Corey
16Fred Hutchinson Cancer Research Center, Seattle, Washington
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen M. Neuzil
2University of Maryland School of Medicine, Baltimore, Maryland
M.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert W. Coombs
15University of Washington Medical Center, Washington
M.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex L. Greninger
15University of Washington Medical Center, Washington
M.D., Ph.D., M.S., M.Phil.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Hutter
3National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie A. Ake
4Walter Reed Army Institute of Research, Maryland
M.D., M.Sc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Smith
1Novavax, Gaithersburg, Maryland
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wayne Woo
1Novavax, Gaithersburg, Maryland
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iksung Cho
1Novavax, Gaithersburg, Maryland
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory M. Glenn
1Novavax, Gaithersburg, Maryland
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filip Dubovsky
1Novavax, Gaithersburg, Maryland
M.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

BACKGROUND Vaccination using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein antigen has been effective in the prevention of coronavirus disease 2019 (Covid-19). NVX-CoV2373 is an adjuvanted, recombinant S protein nanoparticle vaccine that demonstrated clinical efficacy for prevention of Covid-19 in phase 2b/3 trials in the United Kingdom and South Africa.

METHODS This phase 3, randomized, observer-blinded, placebo-controlled trial evaluated the efficacy and safety of NVX-CoV2373 in adults ≥18 years of age in the United States and Mexico during the first quarter of 2021. Participants were randomized in a 2:1 ratio to receive two doses of NVX-CoV2373 or placebo 21 days apart. The primary end point was vaccine efficacy (VE) against reverse transcriptase-polymerase chain reaction-confirmed Covid-19 in SARS-CoV-2-naïve participants ≥7 days after the second dose administration.

RESULTS Of the 29,949 participants randomized between December 27, 2020, and February 18, 2021, 29,582 (median age: 47 years, 12.6% ≥65 years) received ≥1 dose: 19,714 received vaccine and 9868 placebo. In the per-protocol population, there were 77 Covid-19 cases; 14 among vaccine and 63 among placebo recipients (VE: 90.4%, 95% confidence interval [CI] 82.9 to 94.6, P<0.001). All moderate-to-severe cases occurred in placebo recipients, yielding VE of 100% (95% CI 87.0 to 100). Most sequenced viral genomes (48/61, 78.7%) were variants of concern (VOC) or interest (VOI), mainly represented by variant alpha/B.1.1.7 (31/35, 88.6% VOC identified). VE against any VOC/VOI was 92.6% (95% CI 83.6 to 96.7). Reactogenicity was mostly mild-to-moderate and transient, but more frequent in NVX-CoV2373 recipients and after the second dose. Serious adverse events were rare and evenly distributed between treatments.

CONCLUSIONS NVX-CoV2373 was well tolerated and demonstrated a high overall VE (>90%) for prevention of Covid-19, with most cases due to variant strains.

(Funded by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health; PREVENT-19 ClinicalTrials.gov number, NCT04611802.)

Competing Interest Statement

Disclosure forms provided by the authors will be available with the full text of this article upon publication.

Clinical Trial

NCT04611802

Clinical Protocols

https://clinicaltrials.gov/ct2/show/NCT04611802?cond=NCT04611802&draw=2&rank=1

Funding Statement

Funded by Novavax, by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The following Institutional Review Boards / Independent Ethics committees reviewed and approved the study: -Western Copernicus Group IRB, US; Great Plains IRB, US; Comite de etica en investigacion del Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico; Comite de etica en investigacion de la Unidad de Atencion Medica e Investigacion en Salud S.C., Mexico; Comite de etica en investigacion del Instituto Nacional de Salud Publica, Mexico; Comite de etica en investigacion de Medica Rio Mayo S.C., Mexico; Comite de etica en investigacion del Hospital La Mision S.A. de C.V., Mexico All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵** The members of the 2019nCoV-301 Study Group are listed in the Supplementary Appendix.

Data Availability

Data Sharing Statement will be available with the full text of this article upon publication.

https://clinicaltrials.gov/ct2/show/NCT04611802?cond=NCT04611802&draw=2&rank=1

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 10, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
Lisa M. Dunkle, Karen L. Kotloff, Cynthia L. Gay, Germán Áñez, Jeffrey M. Adelglass, Alejandro Q. Barrat Hernández, Wayne L. Harper, Daniel M. Duncanson, Monica A. McArthur, Diana F. Florescu, R. Scott McClelland, Veronica Garcia-Fragoso, Robert A. Riesenberg, David B. Musante, David L. Fried, Beth E. Safirstein, Mark McKenzie, Robert J. Jeanfreau, Jeffrey K. Kingsley, Jeffrey A. Henderson, Dakotah C. Lane, Guillermo M. Ruíz-Palacios, Lawrence Corey, Kathleen M. Neuzil, Robert W. Coombs, Alex L. Greninger, Julia Hutter, Julie A. Ake, Katherine Smith, Wayne Woo, Iksung Cho, Gregory M. Glenn, Filip Dubovsky, for the 2019nCoV-301 Study Group
medRxiv 2021.10.05.21264567; doi: https://doi.org/10.1101/2021.10.05.21264567
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
Lisa M. Dunkle, Karen L. Kotloff, Cynthia L. Gay, Germán Áñez, Jeffrey M. Adelglass, Alejandro Q. Barrat Hernández, Wayne L. Harper, Daniel M. Duncanson, Monica A. McArthur, Diana F. Florescu, R. Scott McClelland, Veronica Garcia-Fragoso, Robert A. Riesenberg, David B. Musante, David L. Fried, Beth E. Safirstein, Mark McKenzie, Robert J. Jeanfreau, Jeffrey K. Kingsley, Jeffrey A. Henderson, Dakotah C. Lane, Guillermo M. Ruíz-Palacios, Lawrence Corey, Kathleen M. Neuzil, Robert W. Coombs, Alex L. Greninger, Julia Hutter, Julie A. Ake, Katherine Smith, Wayne Woo, Iksung Cho, Gregory M. Glenn, Filip Dubovsky, for the 2019nCoV-301 Study Group
medRxiv 2021.10.05.21264567; doi: https://doi.org/10.1101/2021.10.05.21264567

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3284)
  • Dentistry and Oral Medicine (362)
  • Dermatology (276)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1168)
  • Epidemiology (13346)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5138)
  • Geriatric Medicine (480)
  • Health Economics (781)
  • Health Informatics (3260)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (428)
  • HIV/AIDS (1015)
  • Infectious Diseases (except HIV/AIDS) (14617)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4909)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2517)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (542)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (549)
  • Primary Care Research (555)
  • Psychiatry and Clinical Psychology (4198)
  • Public and Global Health (7489)
  • Radiology and Imaging (1703)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (479)
  • Sexual and Reproductive Health (496)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (203)